BiPAP for CO2 Retention

Primary Indications for BiPAP in Hypercapnic Respiratory Failure

The American Thoracic Society recommends BiPAP for patients with hypercapnic respiratory failure, particularly in COPD exacerbations, obesity hypoventilation syndrome, and neuromuscular disease, as it reduces intubation rates, normalizes pH and PaCO2, and improves mortality compared to conventional oxygen therapy 1, 2
BiPAP should be initiated in COPD patients with acute exacerbation when respiratory rate >25 breaths/min with respiratory acidosis (pH <7.35) and elevated PaCO2, as this represents the strongest evidence base for reducing intubation and mortality 2
BiPAP reduces intubation rates by approximately 67% compared to conventional oxygen therapy in COPD patients with acute hypercapnic respiratory failure 2
The European Respiratory Society suggests that BiPAP effectively reverses awake hypercapnia in obesity hypoventilation syndrome patients, with 46.6% achieving PaCO2 <45 mmHg during short-term treatment 1
Both BiPAP and CPAP show similar efficacy for resolving hypercapnia in stable obesity hypoventilation syndrome, though BiPAP may be preferred when significant respiratory muscle fatigue is present 1

Initial BiPAP settings should start with IPAP 15 cmH2O and EPAP 4-5 cmH2O, then rapidly escalate IPAP to 20-30 cmH2O within 10-30 minutes based on patient size and severity of acidosis 2
Typical therapeutic settings include IPAP 14-20 cmH2O and EPAP 4-8 cmH2O for reducing work of breathing 3
Higher IPAP (up to 30 cmH2O) may be required for larger patients or more severe acidosis 2

BiPAP significantly improves pH, reduces PaCO2, and increases PaO2 within 2-4 hours of initiation 2, 3
BiPAP reduces respiratory muscle workload, decreases respiratory rate, and improves sleep efficiency 3
Monitor arterial or venous blood gas (pH, PaCO2), respiratory rate, SpO2, and mental status 2, 4

Imminent respiratory arrest, severe respiratory distress unresponsive to initial BiPAP, or depressed consciousness requires immediate intubation 2
Facial trauma preventing adequate mask seal is an absolute contraindication for BiPAP 3
Persisting pH <7.15 or deteriorating pH despite optimized BiPAP settings indicates failure and need for intubation 2

BiPAP may be associated with higher myocardial infarction rates compared to CPAP in acute heart failure patients, though this remains controversial 5, 6
CPAP should be preferred initially for most acute heart failure patients 4
BiPAP is specifically indicated in heart failure only when hypercapnia is present, there is coexisting COPD, or signs of respiratory muscle fatigue exist 4